Efficacy, Safety, and Tolerability of Atogepant in Migraine Patients from the UAE
Open Access
- 19 May 2026
- journal article
- Published by Springer Nature in Neurology and Therapy
- Vol. 15 (4) , 1763-1775
Abstract
Atogepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for migraine prevention; however, real-world data from the Middle East and North Africa (MENA) region remain limited. This study evaluated the efficacy and safety of atogepant in patients with chronic and episodic migraine in the United Arab Emirates. This retrospective study included adult patients (≥ 18 years) diagnosed with chronic or episodic migraine who received atogepant for at least 6 months. Clinical data were extracted from electronic medical records at the American Center for Psychiatry and Neurology, Abu Dhabi. Monthly migraine days (MMD) at baseline were compared with follow-up MMD documented at visits occurring at least every 2 months. Safety outcomes were assessed through descriptive analysis of reported adverse events (AEs) in the all-exposed population. Sensitivity analyses (non-responder imputation, baseline observation carried forward, multiple imputation under MAR, and tipping point analysis) were conducted to evaluate the robustness of efficacy results in the presence of missing data. Of 86 patients identified, 59 met the inclusion criteria and their data were analyzed. Among these, 39% had chronic migraine and 61% had episodic migraine. The majority were female patients (86.4%) and Emirati nationals (69%). The mean baseline MMD was 12 (SD 8.1), which decreased to 4 (SD 5.2) at the most recent follow-up. Overall, 71% achieved ≥ 50% reduction in MMD, 20% achieved < 50% reduction, and 9% experienced no change. Paired-sample t test demonstrated a significant reduction in MMD t(58) = 9.44, p < 0.001. Adverse events were reported in 10.5% (9/86) of patients, most commonly constipation and nausea. Most patients experiencing AEs (78%) continued treatment, while two discontinued. In this real-world cohort from the UAE, atogepant was associated with significant reductions in monthly migraine days in both patients with chronic and episodic migraine and demonstrated a favorable safety and tolerability profile.Keywords
This publication has 35 references indexed in Scilit:
- Prevalence, Treatment, and Unmet Needs of Migraine in the Middle East: A Systematic ReviewPain and Therapy, 2024
- Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021The Lancet Neurology, 2024
- Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trialThe Lancet Neurology, 2024
- Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2023
- Comparative Efficacy and Safety of Five Anti-calcitonin Gene-related Peptide Agents for Migraine PreventionThe Clinical Journal of Pain, 2023
- Similarities and differences between migraine and other types of headaches: Migraine mimicsNeurology Perspectives, 2023
- Atogepant: First ApprovalDrugs, 2021
- Diagnosis and management of migraine in ten stepsNature Reviews Neurology, 2021
- CGRP as the target of new migraine therapies — successful translation from bench to clinicNature Reviews Neurology, 2018
- Assessing and Managing All Aspects of Migraine: Migraine Attacks, Migraine-Related Functional Impairment, Common Comorbidities, and Quality of LifeMayo Clinic Proceedings, 2009